Jean-Noel David, Managing Director at Seqens CDMO NA, identifies six key trends that promise to reshape the pharma landscape during 2021 and beyond.
Billionaire entrepreneur Mark Cuban – best known as the owner of the Dallas Mavericks and an investor on the ABC business reality series “Shark Tank” – is diving into generic drugs with a new startup, dubbed Mark Cuban Cost Plus Drug Company.
BioSpace presented the NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
Anthos Therapeutics is developing next-generation anticoagulants that do not have the bleeding risks that current blood thinners have.
Blue Knight, a program created in partnership with Johnson & Johnson Innovation and the Biomedical Advanced Research and Development Authority (BARDA), chose seven startups from J&J’s global JLABS incubator network to participate in the fight against the world’s current Covid-19 pandemic and future ones.
Startup IgGenix Inc. emerged from stealth mode with $10 million in Series A financing and a goal to advance the company’s novel antibody therapeutics platform for the treatment of food and non-food allergies, as well as other severe allergic conditions.
Biotech investor Atlas Venture has a new fund that will support the launch of startups in the industry.
This guide explores the different sources of funding available to biotech startups and their relative merits, and how you should best utilize that funding at each stage of your research.
BioSpace presents the NextGen Bio “Class of 2020,” a list of up-and-coming life sciences companies in North America that launched no earlier than mid-2018.
Companies continue to announce advancements in artificial intelligence programming as they harness the power of AI and machine learning to aid in drug discovery and development.